Curemark Opens Autism Trials at New Jersey Site

RYE, N.Y., July 28 /PRNewswire/ -- Curemark, LLC (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.  

Saint Peter's is affiliated with the Drexel University College of Medicine in Philadelphia.  Drexel University College of Medicine began enrolling patients in the CM-AT autism study earlier this year.  Curemark's clinical trial program for CM-AT now encompasses a total of 13 sites nationwide.  

CM-AT, which has received Fast Track status from the FDA, is based on Curemark's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.  

"We are pleased that trial enrollment is proceeding well at Drexel University College of Medicine and that Saint Peter's is also taking part in the clinical research for CM-AT," said Joan Fallon, Curemark founder and CEO.  "We're currently assessing the viability of other possible sites around the country to join the autism study."

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC